Health Care/Hospital

Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market

SOUTHLAKE, Texas, Jan. 8, 2024 /PRNewswire/ -- Novaestiq Corp., a growth-oriented aesthetic and medical dermatological innovations company, focused on delivering a platform of creative solutions to practices and patients, proudly announces its definitive agreement with Croma-Pharma GmbH to be th...

2024-01-08 22:28 1156

YS Biopharma Announces Changes to its Board Committees

GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2024-01-08 21:00 1272

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair

LOS ANGELES, Jan. 8, 2024 /PRNewswire/ -- The ongoing puzzle of having lots of body hair but little on the scalp has confounded many dealing with hair loss. A breakthrough emerges with Dr. U Hair and Skin Clinic reports a pioneering study published in the esteemed Dermatologic Surgery journal tit...

2024-01-08 21:00 1189

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

* Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in m...

2024-01-08 20:30 1249

The World's First Clinical Base Editing Therapy for Hemoglobinopathy

CorrectSequence Therapeutics' CS-101 Successfully Cures One Patient of Transfusion-Dependent β-Thalassemia SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 8, 2024, Shanghai,China, CorrectSequence Therapeutics Co., Ltd. ( Correctseq

2024-01-08 19:46 1540

The L'OCCITANE Group announces evolution in its leadership structure and appoints Laurent Marteau as its new Group CEO

GENEVA, Jan. 8, 2024 /PRNewswire/ -- The L'OCCITANE Group, a pioneer in premium sustainable beauty and wellness and a certified B Corporation™, today announced an evolution in its leadership structure. The responsibilities of Chief Executive Officer (CEO) and Group Managing Director will be combi...

2024-01-08 17:00 4372

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organ...

2024-01-08 16:00 1246

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biops...

2024-01-08 15:30 1158

Make Your 2024 Wish a Reality with Save the Children

Together, Extend Your Festive Warm To Bring More Children's Smile! #SavetheChildrenHK  #ExtendTheSmileOfOurChildren  #SponsorAChild

2024-01-08 12:00 1261

2024 Trend Forecast for Cosmetic Surgery & Medical Aesthetics in Singapore

 As the demand for medical aesthetics and cosmetic surgery continues to grow, Dr Ivan Puah, a liposuction and aesthetic doctor from Amaris B. Clinic, identifies a distinct shift in consumer needs inSingapore. SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Dr Ivan Puah, Medical Director of Amaris B. Cli...

2024-01-08 09:00 403

Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered inSingapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year...

2024-01-08 09:00 1328

Suvoda Announces 30% Growth in 2023 Driven by Strong Customer Adoption of New Suvoda Platform and Products

Company maintained industry-leading quality metrics throughout growth surge. PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease, su...

2024-01-08 08:00 1277

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...

2024-01-05 19:44 2417

Innovations in China's Greater Bay Area: Global Pitch Competition for Startups Announces Winners

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- Thousands of investors, startups, and industry enthusiasts packed the house and tuned in as the 2023 PHBS-CJBS Global Pitch Competition wrapped up. The spectacular grand final event took place in December, revealing the year's winners and other major ...

2024-01-05 18:23 4270

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorpho...

2024-01-05 14:35 1568

Leading New Trends & Stimulating New Vitality, HNC Shenzhen 2023 Came to a Satisfactory Close. See You in Shanghai in 2024.

SHENZHEN, China, Jan. 4, 2024 /PRNewswire/ -- From December 14th to 16th, 2023, the three-day"Healthplex Expo, Natural & Nutraceutical Products Shenzhen 2023" (HNC Shenzhen) came to a successful conclusion at the Shenzhen World Exhibition & Convention Center. Co-organized by CCCMHPIE and Sinoexp...

2024-01-05 10:10 1689

Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice

As the leading percussive patent owner and the driving force behind many of today's wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. LOS ANGELES, Jan. 5, 2024 /PRNewswire/ -- Therabody, the leader in tech wellness and...

2024-01-05 06:33 1825

Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences

Greenway Health™ (Greenway®) offers groundbreaking client-centric electronic health record (EHR) and practice management software that streamline workflows and improve patient outcomes through a unique blend of in-depth insights and cutting-edge technology. SAN ANTONIO, Jan. 5, 2024 /PRNewswire/...

2024-01-05 04:30 2575

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...

2024-01-05 00:19 2095

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...

2024-01-04 21:40 1840
1 ... 30313233343536 ... 554